This technology offers a novel diagnostic tool that predicts prostate cancer treatment outcomes using a chromosomal instability signature based on nine genes. Developed through a multi-omics approach, this signature was identified in prostate epithelial cells experiencing transient centrosome loss—an event known to drive chromosomal instability and aggressive cancer behavior. The gene signature has been validated in multiple patient datasets and is strongly associated with poor clinical outcomes, including higher Gleason scores, increased tumor aggressiveness, and reduced survival. This tool enables early and accurate risk stratification to support personalized treatment decisions. Background: Prostate cancer is one of the leading causes of cancer-related death in men, yet distinguishing between indolent and life-threatening tumors remains a major clinical challenge. Unlike many cancers that present clear driver mutations, prostate cancer has a low mutational burden, making existing diagnostics less effective. Instead, it is characterized by widespread chromosomal instability, which current tools often miss. This diagnostic overcomes that limitation by capturing a CIN-driven molecular signature that more accurately reflects tumor behavior and progression. Applications:
Advantages: